x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

COR2ED - Oncology Medical Conversation

COR2ED Medical Education

Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit

science courses

All Episodes

00:19:43

Prostate cancer: PARP inhibitors. Part 2 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, discuss clinical implementation of PARP inhibitors and novel hormonal agent (NHA) combinationtherapy for patients with mCRPC, providing both a US and EU perspective. In this podcast, the experts discuss efficacy and safety data from the PROPEL study of olaparib

en

00:21:50

Prostate cancer: PARP inhibitors. Part 1 - PARPi...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, discuss clinical implementation of PARP inhibitor monotherapy for prostate cancer patients, providing both a US and EU perspective. In this podcast, the experts discuss the key efficacy and safety findings from the olaparib registration study, PROfound, and the TRITON-2 study which

en

00:21:50

Prostate cancer: PARP inhibitors. Part 1 - PARPi...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, discuss clinical implementation of PARP inhibitor monotherapy for prostate cancer patients, providing both a US and EU perspective. In this podcast, the experts discuss the key efficacy and safety findings from the olaparib registration study, PROfound, and the

en

00:28:03

Endometrial carcinoma: Systemic therapies. Part 2 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Join Lead Nurse Andreia Fernandes and Clinical Nurse Specialist Jo Pearson as they explain how to help patients navigate the side effects of systemic therapies in endometrial carcinoma. Specialist nurses have a critical role helping women stay on treatment and at home for as long as possible. They discuss their privileged position supporting women with endometrial carcinoma and how they continue to educate and advocate for women in a fast-changing therapeutic environment.

en

00:28:03

Endometrial carcinoma: Systemic therapies. Part 2 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Join Lead Nurse Andreia Fernandes and Clinical Nurse Specialist Jo Pearson as they explain how to help patients navigate the side effects of systemic therapies in endometrial carcinoma. Specialist nurses have a critical role helping women stay on treatment and at home for as long as possible. They discuss their privileged position supporting women with endometrial carcinoma and how they continue to educate and advocate for women in a fast-changing therapeutic environment.

en

00:29:25

Endometrial carcinoma: Systemic therapies. Part 1 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Join world-renowned gynaecological oncology experts Dr Domenica “Ketta” Lorusso and Dr Mansoor Mirza as they explore the changing landscape of systemic treatment in endometrial carcinoma. Single-agent immunotherapies (pembrolizumab and dostarlimab), and now immunotherapy and antiangiogenic therapy combinations (pembrolizumab and lenvatinib), are transforming treatment pathways, with OS benefits in the second-line now achievable. They offer tips for managing the toxicity of these novel

en

00:29:25

Endometrial carcinoma: Systemic therapies. Part 1 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Join world-renowned gynaecological oncology experts Dr Domenica “Ketta” Lorusso and Dr Mansoor Mirza as they explore the changing landscape of systemic treatment in endometrial carcinoma. Single-agent immunotherapies (pembrolizumab and dostarlimab), and now immunotherapy and antiangiogenic therapy combinations (pembrolizumab and lenvatinib), are transforming treatment pathways, with OS benefits in the second-line now achievable. They offer tips for managing the toxicity of these

en

00:24:10

Lower GI cancer: Highlights from ASCO GI 2023 - Part 2

COR2ED - Oncology Medical Conversation ·

2023/12/06

This episode, covers the highlights on colorectal cancer from ASCO GI 2023. Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and Prof. Shubham Pant (MD Anderson Cancer Center, Houston, TX, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice. The experts start by discussing the SUNLIGHT trial which studied the use of trifluridine/tipiracil plus bevacizumab as third-line treatment in refractory colorectal cancer. The discussion then

en

00:24:10

Lower GI cancer: Highlights from ASCO GI 2023 - Part 2

COR2ED - Oncology Medical Conversation ·

2023/12/06

This episode, covers the highlights on colorectal cancer from ASCO GI 2023. Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and Prof. Shubham Pant (MD Anderson Cancer Center, Houston, TX, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice. The experts start by discussing the SUNLIGHT trial which studied the use of trifluridine/tipiracil plus bevacizumab as third-line treatment in refractory colorectal cancer.

en

00:25:18

Upper GI cancer Highlights from ASCO GI 2023 - Part 1

COR2ED - Oncology Medical Conversation ·

2023/12/06

This episode, covers the highlights on gastroesophageal, gastric and gastroesophageal junction (GEJ) cancer from ASCO GI 2023. Dr Nataliya Uboha (University of Wisconsin, USA) and Dr Efrat Dotan(Fox Chase Cancer Center, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice. The experts start by covering a number of metastatic studies. First of all, they discuss SPOTLIGHT, a study which investigated the novel agent zolbetuximab as first line treatment in

en

00:25:18

Upper GI cancer Highlights from ASCO GI 2023 - Part 1

COR2ED - Oncology Medical Conversation ·

2023/12/06

This episode, covers the highlights on gastroesophageal, gastric and gastroesophageal junction (GEJ) cancer from ASCO GI 2023. Dr Nataliya Uboha (University of Wisconsin, USA) and Dr Efrat Dotan(Fox Chase Cancer Center, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice. The experts start by covering a number of metastatic studies. First of all, they discuss SPOTLIGHT, a study which investigated the novel agent zolbetuximab as

en

00:22:24

Sarcoma: Updates from CTOS 2022

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast, Prof. Jonathan Trent and Prof. Robin Jones discuss what’s new in the patient management in sarcoma from CTOS 2022. The Connective Tissue Oncology Society is an international group of physicians and scientists with a primary interest in the tumours of connective tissues. With nearly 600 attendees, 10 sessions specific for sarcoma, and over 300 posters, CTOS 2022 took place between November 16 and 19 in Vancouver, BC, Canada. Clinical practice and patient management highlights

en

00:22:24

Sarcoma: Updates from CTOS 2022

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast, Prof. Jonathan Trent and Prof. Robin Jones discuss what’s new in the patient management in sarcoma from CTOS 2022. The Connective Tissue Oncology Society is an international group of physicians and scientists with a primary interest in the tumours of connective tissues. With nearly 600 attendees, 10 sessions specific for sarcoma, and over 300 posters, CTOS 2022 took place between November 16 and 19 in Vancouver, BC, Canada. Clinical practice and patient

en

00:19:51

Advanced RCC: Clinical implementation of targeted...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of Brest and Quimper in France, discuss the clinical implementation of targeted and immunotherapies for advanced renal cell carcinoma (RCC). In this podcast, the two experts discuss data from key trials CHECKMATE 214 (ipilimumab and nivolumab), KEYNOTE 426 (axitinib and pembrolizumab), CHECKMATE 9ER (cabozantinib and nivolumab), CLEAR

en

00:19:51

Advanced RCC: Clinical implementation of targeted...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of Brest and Quimper in France, discuss the clinical implementation of targeted and immunotherapies for advanced renal cell carcinoma (RCC). In this podcast, the two experts discuss data from key trials CHECKMATE 214 (ipilimumab and nivolumab), KEYNOTE 426 (axitinib and pembrolizumab), CHECKMATE 9ER (cabozantinib and nivolumab),

en

00:32:39

Neuroendocrine tumours: The role of SSA at...

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether to continue or not. In patients with well-differentiated Grade 1/2 neuroendocrine tumours (NETs) and slowly progressive asymptomatic disease, potential strategies for continuing SSA at progression include increasing the SSA dose frequency from every four to every two weeks, increasing the monthly SSA dose, using SSA as maintenance therapy in

en

00:32:39

Neuroendocrine tumours: The role of SSA at...

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether to continue or not. In patients with well-differentiated Grade 1/2 neuroendocrine tumours (NETs) and slowly progressive asymptomatic disease, potential strategies for continuing SSA at progression include increasing the SSA dose frequency from every four to every two weeks, increasing the monthly SSA dose, using SSA as maintenance therapy in stable patients unable to

en

00:30:22

HCC: Updates from ILCA and ESMO 2022

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including

en

00:30:22

HCC: Updates from ILCA and ESMO 2022

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late

en

00:21:28

Upper GI cancer: Update from ESMO 2022 - Part 2

COR2ED - Oncology Medical Conversation ·

2023/12/06

This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022. Dr Sam Klempner (Massachusetts General Hospital, Boston, USA) and Dr Yelena Janjigian (Memorial Sloan Kettering Cancer Center, New York, USA) discuss a number of key posters and oral presentations from the meeting and their implications for clinical practice. The experts start by covering a number of first line studies. First of all, they discuss a study from Dr. Janjigian’s

en

183 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter